1. Postmus PE, Kerr KM, Oudkerk M et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv1–iv21.
2. Schneider BJ, Daly ME, Kennedy EB et al. Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: American Society of Clinical Oncology endorsement of the American Soci- ety for Radiation Oncology evidence-based guideline. J Clin Oncol 2018;36:710–9.
3. National Comprehensive Cancer Network. Non-small Cell Lung Cancer. https://www.nccn.org/professionals/physician_gls/ pdf/nscl.pdf . (25 March 2021, date last accessed) (version 4, 2021)
4. Chang JY, Senan S, Paul MA et al. Stereotactic ablative radio- therapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015;16:630–7.
5. Franks KN, McParland L, Webster J et al. SABRTooth: a ran- domised controlled feasibility study of stereotactic ablative radio- therapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of com- plications from surgical resection. Eur RespirJ 2020;56:2000118. https://doi.org/10.1183/13993003.00118-2020.
6. Zheng X, Schipper M, Kidwell K et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non- small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys 2014;90:603–11.
7. Cao C, Wang D, Chung C et al. A systematic review and meta- analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 2019;157:362–73.e8.
8. Zhang B, Zhu F, Ma X et al. Matched-pair comparisons of stereo- tactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiother Oncol 2014;112:250–5. SBRT, lobectomy and SLR in NSCLC • 13
9. Matsuo Y, Chen F, Hamaji M et al. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: a propensity score matching analysis. EurJ Cancer 2014;50:2932–8.
10. Hamaji M, Chen F, Matsuo Y et al. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. Ann Thorac Surg 2015;99:1122–9.
11. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Mul- tivar Behav Res 2011;46:399–424.
12. Elze MC, Gregson J, Baber U et al. Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardio- vascular studies. J Am Coll Cardiol 2017;69:345–57.
13. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975;70:606–12.
14. Takayama K, Nagata Y, Negoro Y et al. Treatment planning of stereotactic radiotherapy for solitary lung tumor. IntJRadiat Oncol Biol Phys 2005;61:1565–71.
15. Matsuo Y, Shibuya K, Nagata Y et al. Prognostic factors in stereo- tactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;79:1104–11.
16. Kato H, Ichinose Y, Ohta M et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N EnglJ Med 2004;350:1713–21.
17. Charlson ME, Pompei P, Ales KL et al. A new method of classify- ing prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
18. Suzuki K, Asamura H, Kusumoto M et al. ‘Early’ peripheral lung cancer: prognostic significance of ground-glass opacity on thin-section computed tomographic scan. Ann Thorac Surg 2002;74:1635–9.
19. Donington J, Ferguson M, Mazzone P et al. American College of Chest Physicians and Society of thoracic surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. Chest 2012;142:1620–35.
20. Schemper M, Smith TL. A note on quantifying follow-up in stud- ies of failure time. Control Clin Trials 1996;17:343–6.
21. McCaffrey DF, Griffin BA, Almirall D et al. A tutorial on propen- sity score estimation for multiple treatments using generalized boosted models. Stat Med 2013;32:3388–414.
22. Hong G. Marginal mean weighting through stratification: a gener- alized method for evaluating multivalued and multiple treatments with nonexperimental data. Psychol Methods 2012;17:44–60.
23. Group AR, Auperin A, Burdett S et al. Adjuvant chemother- apy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. NSCLC meta-analyses collaborative Lancet 2010;375: 1267–77.
24. Vicini FA, Kestin L, Huang R et al. Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer 2003;97:910–9.
25. Junginger T, Goenner U, Trinh TT et al. The link between local recurrence and distant metastases in patients with rectal cancer. Anticancer Res 2019;39:3079–88. 14 • N. Kishi et al.
26. Sullivan DR, Eden KB, Dieckmann NF et al. Understanding patients’ values and preferences regarding early stage lung cancer treatment decision making. Lung Cancer 2019;131:47–57.
27. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71: 209–49.
28. Saito T, Murakawa T, Shintani Y et al. Preoperative renal dys- function and long-term survival after surgery for non-small cell lung cancer. J Thorac Cardiovasc Surg 2021;S0022–5223: 1311–8.
29. Mokhles S, Maat APWM, Aerts JGJV et al. Opinions of lung can- cer clinicians on shared decision making in early-stage non-small- cell lung cancer. Interact Cardiovasc Thorac Surg 2017;25:278–84.
30. Hopmans W, Damman OC, Porsius JT et al. Treatment recom- mendations by clinicians in stage I non-small cell lung cancer: a study of factors that influence the likelihood of accounting for the patient’s preference. Patient Educ Couns 2016;99:1808–13.
31. Hopmans W, Zwaan L, Senan S et al. Differences between pulmo- nologists, thoracic surgeons and radiation oncologists in deciding on the treatment of stage I non-small cell lung cancer: a binary choice experiment. Radiother Oncol 2015;115:361–6.
32. Mokhles S, Nuyttens JJME, de Mol M et al. Treatment selec- tion of early stage non-small cell lung cancer: the role of the patient in clinical decision making. BMC Cancer 2018;18:79. https://doi.org/10.1186/s12885-018-3986-5.
33. Onishi H, Shirato H, Nagata Y et al. Hypofractionated stereotac- tic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi- institutional study. J Thorac Oncol 2007;2:S94–SS100.
34. Moreno AC, Fellman B, Hobbs BP et al. Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage NSCLC. J Thorac Oncol 2020;15:101–9.
35. Kimura T, Nagata Y, Eba J et al. A randomized phase III trial of comparing two dose-fractionations stereotactic body radiother- apy (SBRT) for medically inoperable stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan clinical oncology group study JCOG1408 ( J-SBRT trial). JpnJ Clin Oncol 2017;47:277–81.
36. Saji H, Okada M, Tsuboi M et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer ( JCOG0802/WJOG4607L): a multicentre, open- label, phase 3, randomised, controlled, non-inferiority trial. Lancet 2022;399:1607–17.